General MedicationsINTRAVENOUSStandard
AVASTIN
BEVACIZUMAB
Standard Dose
400MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview AVASTIN is listed in Drugs@FDA under application 125085 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient BEVACIZUMAB Form and strength VIAL; INTRAVENOUS - 400MG Sponsor GENENTECH Submission history Latest submission status date: 2022-09-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview AVASTIN is listed in Drugs@FDA under application 125085 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient BEVACIZUMAB Form and strength VIAL; INTRAVENOUS - 400MG Sponsor GENENTECH Submission history Latest submission status date: 2022-09-18 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.